Lilly declares first-quarter 2026 dividend
Rhea-AI Summary
Eli Lilly (NYSE: LLY) declared a first-quarter 2026 dividend of $1.73 per share on outstanding common stock. The dividend is payable on March 10, 2026 to shareholders of record at the close of business on February 13, 2026.
Positive
- Dividend declared of $1.73 per share for Q1 2026
- Payment date set for March 10, 2026 with record date Feb 13, 2026
Negative
- Cash outflow to shareholders equal to $1.73 per share
News Market Reaction
On the day this news was published, LLY declined 1.26%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
LLY was up 1.16% with higher volume, while large-cap pharma peers were mixed (e.g., JNJ +1.01%, ABBV -0.69%, AZN -0.36%), suggesting a more stock-specific backdrop than a uniform sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 09 | Manufacturing expansion | Positive | -1.5% | Announced >$6B Alabama API facility and thousands of new jobs. |
| Dec 09 | Acquisition completion | Positive | -1.5% | Completed Adverum tender offer with cash plus CVR structure. |
| Dec 09 | Clinical trial data | Positive | -1.5% | Phase 3 Jaypirca data showed 80% lower progression or death risk. |
| Dec 08 | Dividend declaration | Positive | -1.3% | Declared first‑quarter 2026 dividend of $1.73 per share. |
| Dec 08 | Board change | Positive | -1.3% | Reappointed Nobel laureate Carolyn Bertozzi to the board. |
Recent news, including positive clinical, M&A, and governance updates, was followed by modestly negative 24h moves, indicating a tendency for short-term weakness even on constructive headlines.
Over early December 2025, LLY announced several notable developments: a planned $6 billion API facility in Alabama targeting future orforglipron production, completion of the Adverum tender offer, and strong Phase 3 data for Jaypirca in CLL/SLL. Governance news included Carolyn Bertozzi’s return to the board, and the company also set a $1.73 first‑quarter 2026 dividend. Despite these constructive updates, the stock saw -1.26% to -1.54% 24h moves, showing a pattern of short‑term divergence from seemingly positive catalysts.
Market Pulse Summary
This announcement confirmed a first‑quarter 2026 dividend of $1.73 per share, payable on March 10, 2026 to holders of record on February 13, 2026. It extends LLY’s pattern of regular distributions, following multiple $1.50 per‑share dividends in 2025. Investors monitoring this name often track the stability and growth of the dividend alongside capital deployment on manufacturing, acquisitions, and R&D as key indicators of the company’s strategic and financial posture.
AI-generated analysis. Not financial advice.
The dividend is payable on March 10, 2026, to shareholders of record at the close of business on February 13, 2026.
About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. F-LLY
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about expected dividend payments and reflects Lilly's current beliefs and expectations. However, there are significant risks and uncertainties in pharmaceutical research and development, as well as in business development activities and capital allocation strategies related to the company's business and actual results may differ materially due to various factors. For further discussion of risks and uncertainties relevant to Lilly's business that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.
Refer to: | Ashley Hennessey; gentry_ashley_jo@lilly.com; 317-416-4363 (Media) |
Michael Czapar; czapar_michael_c@lilly.com; 317-617-0983 (Investors) |
View original content to download multimedia:https://www.prnewswire.com/news-releases/lilly-declares-first-quarter-2026-dividend-302635673.html
SOURCE Eli Lilly and Company
FAQ
What dividend did Eli Lilly (LLY) declare for Q1 2026?
When is the Eli Lilly (LLY) Q1 2026 dividend payable?
What is the record date for Eli Lilly's (LLY) Q1 2026 dividend?
Who is eligible to receive the Eli Lilly (LLY) Q1 2026 dividend?
How will the Eli Lilly (LLY) dividend be paid for Q1 2026?
Does the Eli Lilly (LLY) announcement change the dividend amount or schedule for 2026?
